Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Glenmark Pharma seeks foreign partners on two biological drugs
BackBack

Glenmark Pharma seeks foreign partners on two biological drugs

The drugs, for the treatment of chronic pain and autoimmune disorders, are in early stage clinical trials on humans

While India’s $15 billion pharmaceutical industry is mainly engaged in developing and selling generic medicines, Glenmark is among the few that continue to invest in the developing original medicines.Premium
While India’s $15 billion pharmaceutical industry is mainly engaged in developing and selling generic medicines, Glenmark is among the few that continue to invest in the developing original medicines.

Mumbai: Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

Glenmark is looking for companies whose research pipelines would complement its experimental drugs, GBR830 and GBR900, which are both in phase 1, or early stage clinical trials on humans, chairman and managing director Glenn Saldanha said.

He declined to give names, but said he expects to find partners by the time the two drugs complete phase 2 clinical trials, which will be “anywhere from a year to two years".

“It will depend on whether the companies are therapeutically focused on that area and whether they have a conflicting molecule in their pipeline," Saldanha said in an interview at Glenmark’s headquarters in Mumbai.

While India’s $15 billion pharmaceutical industry is mainly engaged in the development and sale of generic medicines, Glenmark is among the few that continue to invest in the development of original medicines. Natco Pharma Ltd and Cadila Healthcare Ltd are two other Indian companies also involved in such research.

Glenmark has as many as many as six drugs under development for treatments varying from pain and respiratory disorders to multiple sclerosis, and it has already partnered with US-based Forest Laboratories Ltd and French firm Sanofi SA on two of them.

Glenmark, India’s sixth-largest drug maker by sales, gets about 34% of its revenue from the US, while India is its second-largest market, contributing a quarter of total revenue. Reuters

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 10 Jul 2014, 03:34 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App